Clinical Mechanism Map

{
  "drug_discovery_implications": "BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.",
  "first_in_class_opportunities": [
    "BTK inhibitors for progression (if Phase 3 data positive)",
    "Remyelinating agents (no approved class)"
  ],
  "key_publications": [
    {
      "journal": "Nature Reviews Neurology",
      "title": "BTK inhibitors in progressive MS — mechanisms and clinical data",
      "year": "2024"
    }
  ],
  "mechanism_landscape": {
    "approved_mechanisms": [
      {
        "drugs": [
          "Ocrelizumab",
          "Ofatumumab",
          "Ublituximab"
        ],
        "moa": "Anti-CD20 (B cell depletion)",
        "notes": "Dominant mechanism for RRMS — 3 approved"
      },
      {
        "drugs": [
          "Fingolimod",
          "Siponimod",
          "Ozanimod",
          "Ponesimod"
        ],
        "moa": "S1P receptor modulator",
        "notes": "Oral DMT — 4 approved; class mature"
      },
      {
        "drugs": [],
        "moa": "BTK inhibitor",
        "notes": "No approvals yet — 6 agents in Phase 2/3"
      }
    ],
    "crowded_spaces": [
      "Anti-CD20 (3 approved, 2 in pipeline)",
      "S1P modulators (4 approved)",
      "Natalizumab analogues"
    ],
    "pipeline_mechanisms": [
      {
        "agents": [
          "Fenebrutinib (Roche)",
          "Tolebrutinib (Sanofi)",
          "Evobrutinib (Merck)"
        ],
        "crowding": "Moderate (3 Phase 3)",
        "differentiation": "Targets microglial activation — may address progressive MS unlike existing agents",
        "moa": "BTK inhibition (CNS-penetrant)",
        "phase": "PHASE3"
      },
      {
        "agents": [
          "Opicinumab (Biogen)"
        ],
        "crowding": "Low",
        "differentiation": "Novel — no approved remyelinating agents",
        "moa": "Remyelination (opioid receptor modulation)",
        "phase": "PHASE2"
      }
    ],
    "white_spaces": [
      "Progressive MS neuroprotection",
      "Remyelination",
      "CNS innate immunity",
      "Biomarker-stratified precision approaches"
    ]
  },
  "query_summary": {
    "condition": "Multiple Sclerosis",
    "mechanism": null
  }
}

# bash or zsh: see the payment challenge. Nothing is charged.
curl -sS -g -i 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22'

# x402 v2 sends the challenge base64-encoded in the PAYMENT-REQUIRED header (v1 sends it in the body).
# To read the header:
curl -sS -g -o /dev/null -D - 'https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22' \
  | grep -i '^payment-required:' | cut -d' ' -f2 | tr -d '\r' | base64 --decode

// npm i @x402/fetch @x402/evm viem
import { wrapFetchWithPayment, x402Client } from "@x402/fetch";
import { registerExactEvmScheme } from "@x402/evm/exact/client";
import { privateKeyToAccount } from "viem/accounts";

// Pays at most $0.2 per call.
const client = new x402Client().setSpendControls({ maxAmountPerPayment: "$0.2" });
registerExactEvmScheme(client, { signer: privateKeyToAccount(process.env.EVM_PRIVATE_KEY) });
const pay = wrapFetchWithPayment(fetch, client);

// Not sure it's safe to pay? ToolVet checks it first for $0.005. Pay for that from a separate
// client: this one is capped at $0.2 per payment. GET https://toolvet.app/api/v1/check?url=https%3A%2F%2Fclinicalintelpulse.theaslangroupllc.com%2Fapi%2Fclinical%2Fmechanism-map
const res = await pay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22");
console.log(res.status, await res.text());

# pip install "x402[requests,evm]"
import os
from eth_account import Account
from x402 import x402ClientSync
from x402.http.clients import x402_requests
from x402.mechanisms.evm import EthAccountSigner
from x402.mechanisms.evm.exact.register import register_exact_evm_client

# Pays at most $0.2 per call.
client = x402ClientSync().set_spend_controls({"max_amount_per_payment": "$0.2"})
register_exact_evm_client(client, EthAccountSigner(Account.from_key(os.environ["EVM_PRIVATE_KEY"])))

with x402_requests(client) as session:
    res = session.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map?condition=Disease+%E2%80%94+e.g.+%22Treatment-Resistant+Depression%22+%7C+%22ALS%22+%7C+%22Lupus%22+%7C+%22Multiple+Sclerosis%22+%7C+%22Prostate+Cancer%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&mechanism=Optional+%E2%80%94+specific+mechanism+to+focus+on%2C+e.g.+%22BTK+inhibitor%22+%7C+%22IL-17%22+%7C+%22CAR-T%22")
    print(res.status_code, res.text)